Dominic King

Dominic King

Auto-generated profile, based on publicly available information

Dominic King

Department of Gastroenterology, Sandwell and West Birmingham NHS Trust, West Bromwich, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
DKDominic King
Dominic King
RRRaoul C. Reulen
Raoul C. Reulen
TTTom Thomas
Tom Thomas
JCJoht Singh Chandan
Joht Singh Chandan
RTRasiah Thayakaran
Rasiah Thayakaran
NTNigel Trudgill
Nigel Trudgill
Summary: Background: Data regarding incidence, prevalence and long‐term outcomes of inflammatory bowel diseases in the UK are limited or outdated.Aims: To investigate incidence and prevalence of Crohn's disease and ulcerative colitis and risk of colorectal cancer and all‐cause mortality in these diseases.Methods: Inflammatory bowel disease cases between 2000 and 2018 were identified from a national primary care database. Inflammatory bowel disease prevalence was forecast until 2025. The association between inflammatory bowel disease and colorectal cancer and all‐cause mortality was investigated using age/sex‐matched retrospective cohort studies. Hazard ratios were adjusted for age, sex, deprivation, comorbidity, smoking status and body mass index.Results: Ulcerative colitis prevalence increased from 390 to 570 per 100 000 population from 2000 to 2017. Prevalence of Crohn's disease increased from 220 to 400 per 100 000. In 2017 male Crohn's disease prevalence was 0.35% (95% confidence interval 0.34‐0.36); female prevalence was 0.44% (0.43‐0.45). Prevalence of inflammatory bowel disease is predicted to be 1.1% by 2025. Incidence of ulcerative colitis and Crohn's disease was 23.2 (22.8‐23.6) and 14.3 (14.0‐14.7) per 100 000 person‐years respectively. Subjects with ulcerative colitis were more likely to develop colorectal cancer than controls (adjusted Hazard Ratio 1.40 [1.23‐1.59]). Colorectal cancer rates remained stable in inflammatory bowel diseases over time. Ulcerative colitis and Crohn's disease were associated with increased risk of all‐cause mortality (1.17 [1.14‐1.21] and 1.42 [1.36‐1.48] respectively).Conclusions: The UK prevalence of inflammatory bowel disease is greater than previous reports suggest and we predict an 11% increase in prevalence by the year 2025. Mortality risk in inflammatory bowel disease and colorectal cancer risk in ulcerative colitis are increased compared to matched controls.

30 June 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
NUNosheen Umar
Nosheen Umar
DKDominic King
Dominic King
JCJoht Singh Chandan
Joht Singh Chandan
NBNeeraj Bhala
Neeraj Bhala
KNKrish Nirantharakumar
Krish Nirantharakumar
NTNigel Trudgill
Nigel Trudgill

31 August 2022 in Endoscopy
Verified
Journal Article
Closed access
PDF file
UKUmair Kamran
Umair Kamran
DKDominic King
Dominic King
AAAbdullah Abbasi
Abdullah Abbasi
BCBen Coupland
Ben Coupland
NUNosheen Umar
Nosheen Umar
NTNigel J. Trudgill
Nigel J. Trudgill
Background Missing upper gastrointestinal cancer (UGIC) at endoscopy may prevent curative treatment. We have developed a root cause analysis system for potentially missed UGICs at endoscopy (post-endoscopy UGIC [PEUGIC]) to establish the most plausible explanations.Methods The electronic records of patients with UGIC at two National Health Service providers were examined. PEUGICs were defined as UGICs diagnosed 6–36 months after an endoscopy that did not diagnose cancer. An algorithm based on the World Endoscopy Organization post-colonoscopy colorectal cancer algorithm was developed to categorize and identify potentially avoidable PEUGICs.Results Of 1327 UGICs studied, 89 (6.7 %) were PEUGICs (patient median [IQR] age at endoscopy 73.5 (63.5–81.0); 60.7 % men). Of the PEUGICs, 40 % were diagnosed in patients with Barrett’s esophagus. PEUGICs were categorized as: A – lesion detected, adequate assessment and decision-making, but PEUGIC occurred (16.9 %); B – lesion detected, inadequate assessment or decision-making (34.8 %); C – possible missed lesion, endoscopy and decision-making adequate (8.9 %); D – possible missed lesion, endoscopy or decision-making inadequate (33.7 %); E – deviated from management pathway but appropriate (5.6 %); F – deviated inappropriately from management pathway (3.4 %). The majority of PEUGICs (71 %) were potentially avoidable and in 45 % the cancer outcome could have been different if it had been diagnosed on the initial endoscopy. There was a negative correlation between endoscopists’ mean annual number of endoscopies and the technically attributable PEUGIC rate (correlation coefficient −0.57; P = 0.004).Conclusion Missed opportunities to avoid PEUGIC were identified in 71 % of cases. Root cause analysis can standardize future investigation of PEUGIC and guide quality improvement efforts.

12 November 2019 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
DKDominic King
Dominic King
JRJames Rees
James Rees
JMJemma Mytton
Jemma Mytton
PHPhilip Harvey
Philip Harvey
TTTom Thomas
Tom Thomas
NTNigel Trudgill
Nigel Trudgill
Background and Aims: Patients with ulcerative colitis [UC] may present as emergencies and require rapid escalation of therapy. This study aimed to assess the mortality, colectomy, and readmission risks, during and following a first emergency admission with UC. Methods: Using Hospital Episode Statistics, subjects aged between 18 and 60 years, coded with a first emergency admission with UC, were identified between 2007 and 2017. Influences of demographic factors, comorbidity, anti-tumour necrosis factor [TNF] therapy, and provider UC activity on mortality and colectomy were examined. Results: A total of 10 051 subjects (46% female; median age 33 years [interquartile range [IQR] 25–44]) were identified. Mortality was 0.2% in hospital and 0.5% at 12 months and, following colectomy during acute admission, it was 1.4% in hospital and 2.1% at 12 months. Females had reduced risk of colectomy during admission: odds ratio [OR] 0.73 (95% confidence interval [CI] 0.62–0.85). Comparing the period 2007–2011 with 2012–2017, the rate of colectomy fell during acute admissions: OR 0.85 [0.72–0.99], p = 0.038 and at 12 months after admission: OR 0.73 [0.61–0.87]. Anti-TNF therapy increased 4-fold in acute UC admissions from 2007–2017. Those receiving anti-TNF therapy had a 70% increased risk of colectomy during index admission compared with those not receiving anti-TNF: OR 1.72 [1.29–2.31]. Increased time to colectomy during first admission was associated with female sex: hazard ratio [HR] 0.84 [0.72–0.98] and Asian ethnicity: HR 0.61 [0.44–0.85], whereas reduced time was associated with increased comorbidity, lower deprivation, and high provider volume of colectomies for UC: HR 1.59 [1.31–1.93]. Conclusions: Mortality following colectomy was 1.4% in hospital and 2.1% at 12 months, and no significant change over time was observed. Colectomy during emergency admission for UC was less common in females. Rates of anti-TNF therapy during emergency admission for UC have increased and overall colectomy rates have fallen. Podcast: This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast

11 May 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
DKDominic King
Dominic King
JCJoht Singh Chandan
Joht Singh Chandan
TTTom Thomas
Tom Thomas
ADAlastair K Denniston
Alastair K Denniston
TBTasanee Braithwaite
Tasanee Braithwaite
NTNigel J Trudgill
Nigel J Trudgill
Objectives Ophthalmic conditions including anterior uveitis (AU), episcleritis and scleritis may occur in association with the inflammatory bowel diseases (IBD) as ophthalmic extraintestinal manifestations. The aim of this study was to assess the risk of a later IBD diagnosis in those presenting with IBD associated ocular inflammation (IAOI). Design Retrospective cohort study. Setting Primary care UK database. Participants 38 805 subjects with an IAOI were identified (median age 51 (38–65), 57% women) and matched to 153 018 subjects without IAOI. Measures The risk of a subsequent diagnosis of IBD in subjects with IAOIs compared with age/sex matched subjects without IAOI. HRs were adjusted for age, sex, body mass index, deprivation, comorbidity, smoking, baseline axial arthropathy, diarrhoea, loperamide prescription, anaemia, lower gastrointestinal bleeding and abdominal pain. Logistic regression was used to produce a prediction model for a diagnosis of IBD within 3 years of an AU diagnosis. Results 213 (0.6%) subsequent IBD diagnoses (102 ulcerative colitis (UC) and 111 Crohn’s disease (CD)) were recorded in those with IAOIs and 329 (0.2%) (215 UC and 114 CD) in those without. Median time to IBD diagnosis was 882 (IQR 365–2043) days in those with IAOI and 1403 (IQR 623–2516) in those without. The adjusted HR for a subsequent diagnosis of IBD was 2.25 (95% CI 1.89 to 2.68), p<0.001; for UC 1.65 (95% CI 1.30 to 2.09), p<0.001; and for CD 3.37 (95% CI 2.59 to 4.40), p<0.001 in subjects with IAOI compared with those without. Within 3 years of an AU diagnosis, 84 (0.5%) subjects had a recorded diagnosis of IBD. The prediction model performed well with a C-statistic of 0.75 (95% CI 0.69 to 0.80). Conclusions Subjects with IAOI have a twofold increased risk of a subsequent IBD diagnosis. Healthcare professionals should be alert for potential signs and symptoms of IBD in those presenting with ophthalmic conditions associated with IBD.

31 March 2022 in Endoscopy
Verified
Journal Article
Closed access
PDF file
DKDominic King
Dominic King
UKUmair Kamran
Umair Kamran
ADAmandeep Dosanjh
Amandeep Dosanjh
BCBen Coupland
Ben Coupland
JMJemma Mytton
Jemma Mytton
NTNigel J. Trudgill
Nigel J. Trudgill
Background Data are limited regarding pancreatic cancer diagnosed following a pancreaticobiliary endoscopic ultrasound (EUS) that does not diagnose pancreatic cancer. We have studied the frequency of, and factors associated with, post-EUS pancreatic cancer (PEPC) and 1-year mortality. Methods Between 2010 and 2017, patients with pancreatic cancer and a preceding pancreaticobiliary EUS were identified in a national cohort using Hospital Episode Statistics. Patients with a pancreaticobiliary EUS 6–18 months before a later pancreatic cancer diagnosis were the PEPC cases; controls were those with pancreatic cancer diagnosed within 6 months of pancreaticobiliary EUS. Multivariable logistic regression models examined the factors associated with PEPC and a Cox regression model examined factors associated with 1-year cumulative mortality. Results 9363 pancreatic cancer patients were studied; 93.5 % identified as controls (men 53.2 %; median age 68 [interquartile range (IQR) 61–75]); 6.5 % as PEPC cases (men 58.2 %; median age 69 [IQR 61–77]). PEPC was associated with older age (≥ 75 years compared with < 65 years, odds ratio [OR] 1.42, 95 %CI 1.15–1.76), increasing co-morbidity (Charlson co-morbidity score > 5, OR 1.90, 95 %CI 1.49–2.43), chronic pancreatitis (OR 3.13, 95 %CI 2.50–3.92), and diabetes mellitus (OR 1.58, 95 %CI 1.31–1.90). Metal biliary stents (OR 0.57, 95 %CI 0.38–0.86) and EUS-FNA (OR 0.49, 95 %CI 0.41–0.58) were inversely associated with PEPC. PEPC was associated with a higher cumulative mortality at 1 year (hazard ratio 1.12, 95 %CI 1.02–1.24), with only 14 % of PEPC patients (95 %CI 12 %–17 %) having a surgical resection, compared with 21 % (95 %CI 20 %–22 %) of controls. Conclusions PEPC occurred in 6.5 % of patients and was associated with chronic pancreatitis, older age, more co-morbidities, and specifically diabetes mellitus. PEPC was associated with a worse prognosis and lower surgical resection rates. * Joint first authors Received: 10 May 2021 Accepted: 10 February 2022 Publication Date: 31 March 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany